EP1198471A1

EP1198471A1 - Process for deacylation of lipodepsipeptides

Info

Publication number: EP1198471A1
Application number: EP00938006A
Authority: EP
Inventors: Adam Joseph Kreuzman; Palaniappan Kulanthaivel; Michael John Rodriguez
Original assignee: Eli Lilly and Co
Current assignee: Eli Lilly and Co
Priority date: 1999-07-15
Filing date: 2000-06-08
Publication date: 2002-04-24
Also published as: MXPA02000458A; AU5310600A; CA2378868A1; HUP0202315A2; BR0012481A; JP2003505042A; CN1361791A; NO20020183L; EA200200162A1; NO20020183D0; WO2001005815A1

Abstract

A process is described for deacylating a lipodepsipeptide to produce the corresponding nucleus. The products produced from this process is also described (e.g., a pseudomycin nucleus represented by structures (I) or (II)).

Description

PROCESS FOR DEACYLATION OF LIPODEPSIPEPTIDES

FIELD OF THE INVENTION The present invention relates to lipodepsipeptides, in particular, deacylation of the N-acyl side-chain of pseudomycin and syringomycin natural products and the compounds produced therefrom.

BACKGROUND OF THE INVENTION

Pseudomycins and syringomycins are natural products isolated from liquid cultures of Pseudomonas syringae (plant-associated bacterium) and have been shown to have antifungal activities. (see i.e., Harrison, L., et al . , "Pseudomycins, a family of novel peptides from Pseudomonas syringae possessing broad-spectrum antifungal activity, " J. Gen. Microbiology, 137(12), 2857-65 (1991) and US Patent Nos. 5,576,298 and 5,837,685) Unlike the previously described antimycotics from P. syringae (e.g., syringomycins, syringotoxins and syringostatins) , pseudomycins A-C contain hydroxyaspartic acid, aspartic acid, serine, dehydroaminobutyric acid, lysine and diaminobutyric acid.

The peptide moiety for pseudomycins A, A', B, B' , C, C corresponds to L-Ser-D-Dab-L-Asp-L-Lys-L-Dab-L-aThr-Z-Dhb-L- Asp(3-OH) -L-Thr (4-C1) with the terminal carboxyl group closing a macrocyclic ring on the OH group of the N-terminal Ser. The analogs are distinguished by the N-acyl side chain, i.e., pseudomycin A is N-acylated by 3 , 4-dihydroxytetradeconoyl, pseudomycin A' by 3 , 4-dihydroxypentadecanoyl , pseudomycin B by 3-hydroxytetradecanoyl, pseudomycin B' by 3-hydroxydodecanoyl, pseudomycin C by 3 , 4-dihydroxyhexadecanoyl and pseudomycin C by 3-hydroxyhexadecanoyl . (see i.e., Ballio, A., et al . , "Novel bioactive lipodepsipeptides from Pseudomonas syringae : the pseudomycins," FEBS Letters, 355(1), 96-100, (1994) and Coiro, V.M. , et al . , "Solution conformation of the Pseudomonas syringae MSU 16H phytotoxic lipodepsipeptide Pseudomycin A determined by computer simulations using distance geometry and molecular dynamics from NMR data, " Eur. J. Biochem. , 257(2), 449-456 (1998).)

Pseudomycins and syringomycins are known to have certain adverse biological effects. For example, destruction of the endothelium of the vein, destruction of tissue, inflammation, and local toxicity to host tissues have been observed when pseudomycin is administered intraveneously . Therefore, there is a need to identify compounds within this class that are useful for treating fungal infections without the currently observed adverse side effects. BRIEF SUMMARY OF THE INVENTION The present invention provides a process for deacylating the N-acyl side-chain of a lipodepsipeptide natural product to produce the corresponding nucleus. The deacylation of pseudomycin compounds produces the pseudomycin amino nucleus represented by the following structure I.

The nucleus is useful as a starting material for producing semi-synthetic derivatives of the corresponding natural product.

The process includes reacting a pseudomycin natural product with a deacylase enzyme selected from the group consisting of ECB deacylase and polymyxin acylase to produce the corresponding nucleus represented by structure I . The free amine may rearrange to produce a cyclic peptide nucleus having a free hydroxy group represented by structure II below (also referred to as pseudomycin hydroxy nucleus) .

II

Compound II may then serve as starting material to generate novel derivatives which may be pharmaceutically active.

In another embodiment of the present invention, the process described above is used to deacylate syringomycin compounds to provide a syringomycin amino nucleus. For example, the amino nucleus of Syringomycin E has the following structure III.

III

Like the pseudomycin amino nucleus, the syringomycin amino nucleus may rearrange to form the following Compound IV (also referred to as syringomycin hydroxy nucleus) .

IV Even though specific chiral forms are depicted above for Compounds I, II, III and IV, other chiral forms are within the spirit of the present invention. Each of the compounds may also exist as pharmaceutically acceptable salts, hydrates or solvates thereof.

Definitions

As used herein, the term "pseudomycin" refers to compounds having the following formula:

where R is a lipophilic moiety. The lipophilic moiety includes C₉-C₁₅ alkyl, C₉-C₁₅ hydroxyalkyl , C₉-C₁₅ dihydroxya1ky1 , C₉-C₁₅ alkenyl, C₉-C1₅ hydroxyalkenyl, or C₉- C1₅ dihydroxyalkenyl . The pseudomycin compounds A, A', B, B', C, C are represented by the formula I above where R is as defined below.

Pseudomycin A R = 3 , 4-dihydroxytetradecanoyl

Pseudomycin A' R = 3 , 4-dihydroxypentadecanoyl Pseudomycin B R = 3-hydroxytetradecanoyl

Pseudomycin B' R = 3-hydroxydodecanoyl

Pseudomycin C R = 3 , 4-dihydroxyhexadecanoyl

Pseudomycin C R = 3-hydroxyhexadecanoyl

DETAILED DESCRIPTION OF THE INVENTION

Applicants have discovered a process for enzymatically deacylating the N-acyl side-chain of a broad spectrum of lipodepsipeptide natural products to produce the corresponding nucleus. Surprisingly, the free amine nucleus rearranges to produce the free hydroxy derivative such as the compounds shown above as structures II and IV. Compounds I and III can be converted to Compounds II and IV, respectively, by exposing Compound I or III to a pH > 6. If the desired product is Compound I or III, then one could reduce the rate at which the rearranged product forms from the deacylated pseudomycin or deacylated syringomycin with the addition of an acid, such as trifluoroacetic acid. However, the addition of an acid could result in lower yields of the amine nucleus. At lower pHs, the enzyme may precipitate out of the reaction mixture thus stopping the conversion. Therefore, the pH of the reaction mixture is preferably not lowered less than about 5.5. One could prevent enzyme precipitation by separating the enzyme from the reaction through a molecular weight membrane (i.e., 10,000 to 50,000 molecular weight cutoff). The effluent through the membrane would contain compounds having a molecular weight less than 10,000 to 5,000 (e.g., Compounds I-IV) and would exclude the higher molecular weight enzyme. The effluent could then be pH adjusted down to stabilize the product.

Unlike acid deacylation processes (e.g., trifluoroacetic acid in an aqueous solvent at room temperature) , the inventive enzymatic process may be used to deacylate pseudomycin or syringomycin analogs with or without gamma or delta hydroxy side chains. Therefore, the spectrum of starting natural products is expanded significantly. For example, one may deacylate pseudomycin A, A', B, B', C or C using the inventive process. Whereas, the acid deacylation process is useful only with pseudomycin A, A' and C.

Suitable enzymes include ECB deacylase and Polymyxin acylase (available in both a crude & pure form as 161-16081 Fatty Acylase, Pure and 164-16081 Fatty Acylase, Crude, from Wako Pure Chemical Industries, Ltd.) ECB deacylase can be obtained from Actinoplanes utahensis (see e.g., LaVerne, D, et al, "Deacylation of Echinocandin B by Actinoplanes utahensis, " J. of Antibiotics , 42(3), 382-388 (1989).) The Actinoplanes utahensis ECB deacylase enzyme may be purified by the process described in U.S. Patent No. 5,573,936, incorporated herein by reference. One may also use an enzyme that has been cloned and expressed in Streptomyces lividans . Attempts to deacylate pseudomycin A with Pen G Amidase and Phthalyl Amidase were not successful.

The enzymatic deacylation may be accomplished using standard deacylation procedures well known to those skilled in the art. For example, general procedures for using Polymyxin acylase may be found in Yasuda, N. , et al, Agri c . Biol . Chem. , 53, 3245 (1989) and Kimura, Y., et al . , Agric . Biol . Chem. , 53, 497 (1989).

The deacylation process is generally ran at temperatures between about 20°C and about 60°C, preferably

between about room temperature (25°C) and about 40°C. Higher temperatures may promote the formation of the rearranged product (Compound II) . The enzyme is optimally active at pH 8.0 and at a temperature between about 50°C and

60°C. Although the reaction is faster at the higher pH and higher temperature, more rearranged product may be observed at the higher pH. Therefore, the pH of the reaction is generally kept between about 5.5 and about 8.0. The reaction time will vary depending upon the pH and the temperature. However, with limiting enzyme concentration and saturated substrate concentration at high temperatures and pH, the reaction is linear through 10 minutes. Since Pseudomcyin A is unstable at higher pHs, deacylation of Pseudomycin A is generally ran at a lower pH (between about

5.0 and 6.0) and temperature (about 25°C) . For example, deacylation of Pseudomycin A can be ran in a buffered solution containing 0.05 M KP0₄ and 0.8 M KC1. A saturated level of substrate is generally between about 0.5 mg and about 1 mg per ml of reaction.

As discussed earlier, pseudomycins are natural products isolated from the bacterium Pseudomonas syringae that have been characterized as lipodepsinonapetpides containing a cyclic peptide portion closed by a lactone bond and including the unusual amino acids 4-chlorothreonine (ClThr) , 3-hydroxyaspartic acid (HOAsp) , 2 , 3-dehydro-2-aminobutyric acid (Dhb) , and 2 , 4-diaminobutyric acid (Dab). Methods for growth of various strains of P. syringae to produce the different pseudomycin analogs (A, A', B, B' , C, and C) are generally described below and also described in more detail in PCT Patent Application Serial No. PCT/US00/08728 filed by Hilton, et al . on April 14, 2000 entitled "Pseudomycin Production by Pseudomonas Syringae, " incorporated herein by reference, PCT Patent Application Serial No. PCT/US00/08727 filed by Kulanthaivel, et al . on April 14, 2000 entitled "Pseudomycin Natural Products," incorporated herein by reference, and U.S. Patent Nos . 5,576,298 and 5,837,685, each of which are incorporated herein by reference.

Isolated strains of P. syringae that produce one or more pseudomycins are known in the art. Wild type strain MSU 174 and a mutant of this strain generated by transposon mutagenesis, MSU 16H are described in U.S. Patent Nos. 5,576,298 and 5,837,685; Harrison, et al . , "Pseudomycins, a family of novel peptides from Pseudomonas syringae possessing broad-spectrum antifungal activity, " J . Gen . Microbiology, 137, 2857-2865 (1991); and Lamb et al . , "Transposon mutagenesis and tagging of fluorescent pseudomonas: Antimycotic production is necessary for control of Dutch elm disease," Proc . Natl . Acad. Sci . USA, 84, 6447- 6451 (1987) .

A strain of P. syringae that is suitable for production of one or more pseudomycins can be isolated from environmental sources including plants (e.g., barley plants, citrus plants, and lilac plants) as well as, sources such as soil, water, air, and dust. A preferred stain is isolated from plants. Strains of P. syringae that are isolated from environmental sources can be referred to as wild type. As used herein, "wild type" refers to a dominant genotype which naturally occurs in the normal population of P. syringae ( e . g . , strains or isolates of P. syringae that are found in nature and not produced by laboratory manipulation) . Like most organisms, the characteristics of the pseudomycin- producing cultures employed (P. syringae strains such as MSU 174, MSU 16H, MSU 206, 25-B1, 7H9-1) are subject to variation. Hence, progeny of these strains (e.g., recombinants, mutants and variants) may be obtained by methods known in the art.

Mutant strains of P. syringae are also suitable for production of one or more pseudomycins. As used herein, "mutant" refers to a sudden heritable change in the phenotype of a strain, which can be spontaneous or induced by known mutagenic agents, such as radiation (e.g., ultraviolet radiation or x-rays), chemical mutagens (e.g., ethyl methanesulfonate (EMS) , diepoxyoctane, N-methyl-N- nitro-N' -nitrosoguanine (NTG) , and nitrous acid), site- specific mutagenesis, and transposon mediated mutagenesis. Pseudomycin-producing mutants of P. syringae can be produced by treating the bacteria with an amount of a mutagenic agent effective to produce mutants that overproduce one or more pseudomycins, that produce one pseudomycin (e.g., pseudomycin B) in excess over other pseudomycins, or that produce one or more pseudomycins under advantageous growth conditions. While the type and amount of mutagenic agent to be used can vary, a preferred method is to serially dilute

NTG to levels ranging from 1 to 100 μg/ml. Preferred mutants are those that overproduce pseudomycin B and grow in minimal defined media.

Environmental isolates, mutant strains, and other desirable strains of P. syringae can be subjected to selection for desirable traits of growth habit, growth medium nutrient source, carbon source, growth conditions, amino acid requirements, and the like. Preferably, a pseudomycin producing strain of P. syringae is selected for growth on minimal defined medium such as N21 medium and/or for production of one or more pseudomycins at levels greater than about 10 μg/ml. Preferred strains exhibit the characteristic of producing one or more pseudomycins when grown on a medium including three or fewer amino acids and optionally, either a lipid, a potato product or combination thereof .

Recombinant strains can be developed by transforming the P. syringae strains, using procedures known in the art. Through the use of recombinant DNA technology, the P. syringae strains can be transformed to express a variety of gene products in addition to the antibiotics these strains produce. For example, one can modify the strains to introduce multiple copies of the endogenous pseudomycin- biosynthesis genes to achieve greater pseudomycin yield.

To produce one or more pseudomycins from a wild type or mutant strain of P. syringae, the organism is cultured with agitation in an aqueous nutrient medium including an effective amount of three or fewer amino acids, preferably glutamic acid, glycine, histidine, or a combination thereof. Alternatively, glycine is combined with one or more of a potato product and a lipid. Culturing is conducted under conditions effective for growth of P. syringae and production of the desired pseudomycin or pseudomycins . Effective conditions include temperatures from about 22²C to about 27²C, and a duration of about 36 hours to about 96 hours. Controlling the concentration of oxygen in the medium during culturing of P . syringae is advantageous for production of a pseudomycin. Preferably, oxygen levels are maintained at about 5 to 50% saturation, more preferably about 30% saturation. Sparging with air, pure oxygen, or gas mixtures including oxygen can regulate the concentration of oxygen in the medium.

Controlling the pH of the medium during culturing of P. syringae is also advantageous. Pseudomycins are labile at basic pH, and significant degradation can occur if the pH of the culture medium is above about 6 for more than about 12 hours. Preferably, the pH of the culture medium is maintained between 6 and 4. P. syringae can produce one or more pseudomycins when grown in batch culture. However, fed-bath or semi-continuous feed of glucose and optionally, an acid or base (e.g., ammonium hydroxide) to control pH, enhances production. Pseudomycin production can be further enhanced by using continuous culture methods in which glucose and ammonium hydroxide are fed automatically.

Choice of P. syringae strain can affect the amount and distribution of pseudomycin or pseudomycins produced. For example, strains MSU 16H and 67 HI each produce predominantly pseudomycin A, but also produce pseudomycin B and C, typically in ratios of 4:2:1. Strain 67 Hi typically produces levels of pseudomycins about three to five fold larger than are produced by strain MSU 16H. Compared to strains MSU 16H and 67 Hi, strain 25-B1 produces more pseudomycin B and less pseudomycin C. Strain 7H9-1 are distinctive in producing predominantly pseudomycin B and larger amount of pseudomycin B than other strains . For example, this strain can produce pseudomycin B in at least a ten fold excess over either pseudomycin A or C .

As discussed earlier, the process described herein is also useful for deacylating syringomycin compounds . Syringomycin E, syringotoxin B, and syringostatin A may be produced from cultures of Pseudomonas syringae pv. syringae strains B301D, PS268, and SY12, respectively. Syringomycin Ai and G may be isolated from Pseudomonas syringae pv. syringae as well. Strains B301D and PS268 are grown in potato dextrose broth as described by Zhang, L., and J. Y. Takemoto, "Effects of Pseudomonas syringae phytotoxin, syringomycin, on plasma membrane functions of Rhodotorula pilimanae," Phytopathol . 77 (2 ): 297-303 (1987). Strain SY12 was grown in syringomycin minimal medium supplemented with 100M arbutin (Sigma Chemical Co., A 4256; St. Louis, Mo.) and 0.1% fructose (SRMAF) (19, 23). SR-E, ST-B, and SS-A are purified by high performance liquid chromatography as described previously by Bidwai, A. P., and J. Y. Takemoto, "Bacterial phytotoxin, syringomycin, induces a protein kinase-mediatedphosphorylation of red beet plasma membrane polypeptides, " Proc . Natl . Acad. Sci . USA, 84:6755-6759 (1987) . Solubilized AmB containing 35% sodium deoxycholate (Sigma Chemical Co., A 9528; St. Louis, Mo.) and ketoconazole (Sigma Chemical Co., K-1003; St. Louis, Mo.) are used as test standards. A detailed description for the production and isolation of three cyclic lipodepsinonapeptides syringomycin E, syringotoxin B, and syringostatin A may be found in U.S. Patent No. 5,830,855, incorporated herein by reference.

The pseudomycin or syringomycin nucleus or corresponding rearranged compounds (Compounds II and IV) may be isolated and used per se or in the form of its pharmaceutically acceptable salt or solvate. The term "pharmaceutically acceptable salt" refers to non-toxic acid addition salts derived from inorganic and organic acids. Suitable salt derivatives include halides, thiocyanates, sulfates, bisulfates, sulfites, bisulfites, arylsulfonates, alkylsulfates, phosphonates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphonates, alkanoates, cycloalkylalkanoates, arylalkonates , adipates, alginates, aspartates, benzoates, fumarates, glucoheptanoates, glycerophosphates, lactates, maleates, nicotinates, oxalates, palmitates, pectinates, picrates, pivalates, succinates, tartarates, citrates, camphorates, camphorsulfonates, digluconates, trifluoroacetates, and the like. The term "solvate" refers to an aggregate that comprises one or more molecules of the solute (i.e., pseudomycin and syringomycin compound) with one or more molecules of a pharmaceutical solvent, such as water, ethanol, and the like. When the solvent is water, then the aggregate is referred to as a hydrate. Solvates are generally formed by dissolving the nucleus or rearranged compound (Compounds II or IV) in the appropriate solvent with heat and slowing cooling to generate an amorphous or crystalline solvate form. EXAMPLES Biological Samples

P. syringae MSU 16H is publicly available from the

American Type Culture Collection, Parklawn Drive, Rockville, MD, USA as Accession No. ATCC 67028. P. syringae strains

25-Bl, 7H9-1, and 67 Hi were deposited with the American

Type Culture Collection on March 23, 2000 and were assigned the following Accession Nos.:

25-Bl Accession No. PTA-1622 7H9-1 Accession No. PTA-1623

67 Hi Accession No. PTA-1621

Chemical Abbreviations

The following abbreviations are used through out the examples to represent the respective listed materials:

ACN - acetonitrile

TFA - trifluoroacetic acid

DMF - dimethylformamide

Example 1

Example illustrates the deacylation of Pseudomycin A using ECB Deacylase enzyme .

Pseudomycin A (50 μg) and purified ECB Deacylase (50

μl) in 900 μl of an aqueous buffer solution containing 0.05 M potassium phosphate and 0.8 M potassium chloride. The pH remained between 6.0 and 8.0. The temperature was increased from 25°C to 40°C. The reaction was monitored by HPLC

(Waters C18 μBondapak 3.9 X 300 mm column, 235 n , 1% acetonitrile/0.2% trifluoroacetic acid (4 minutes) to 60% acetonitrile/0.2% trifluoroacetic acid (16 minutes)). Both the pseudomycin amine nucleus (Compound I) and the rearranged pseudomycin hydroxy nucleus (Compound II) were observed.

Both Compounds I and II showed identical M+H ion (m/z 981.3) in the electrospray ionization mass spectroscopy (ESIMS) corresponding to a molecular formula of

C₃₇H₆ιClNι₂0ι₇. (See Table I below) Detailed analysis of ¹H and TOCSY (total correlation spectroscopy) NMR spectra enabled the assignment of all protons for the hydrolysis products which supports structures I and II. The ¹H NMR chemical shifts of the β-protons (4.83 and 4.46 ppm) of the serine residue of I were consistent with those found in pseudomycins A, B and C, indicating that the peptide macrocycle was intact. Furthermore, as expected, the TOCSY spectrum did not show the typical amide proton as part of the serine spin system. On the other hand, in II the serine

β-protons underwent considerable upfield shifts (3.78 and 3.74 ppm) suggesting that these protons were not bearing the lactone functionality. This and the fact that the β-

protons, in addition to the proton, correlated to an amide proton at 8.04 ppm in the TOCSY spectrum indicated that the lactone of the macrocycle rearranged to a peptide core as depicted in II.

Table I

^XH NMR data^a of I and II in H₂0+CD₃CN

Table I (continued)

^a Chemical shifts reported are relative to solvent signal (1.94 ppm) . ^b Assignments may be interchanged.

Other pseudomycin or syringomycin compounds having an N-acyl group may be deacylated using the same general procedures described above .

Claims

WE CLAIM :

1. A process for deacylating an N-acyl side-chain of a pseudomycin natural product comprising the step of reacting a pseudomycin natural product with a deacylating enzyme selected from the group consisting of ECB deacylase and polymyxin acylase to produce a pseudomycin nucleus .

2. The process of Claim 1 wherein said pseudomycin nucleus is represented by either structure I or II

II or a pharmaceutically acceptable salt, hydrate or solvate thereof .

3. The process of Claim 1 wherein said pseudomycin natural product is selected from the group consisting of pseudomycin A, A', B, B', C, and C.

A compound having the following structure

or a pharmaceutically acceptable salt, hydrate or solvate thereof, prepared by the process of Claims 1, 2 or 3.

5. A compound having the following structure

or a pharmaceutically acceptable salt, hydrate or solvate thereof .

6. A pseudomycin nucleus prepared by reacting a pseudomycin natural product with a deacylating enzyme selected from the group consisting of ECB deacylase and polymyxin acylase .

7. The pseudomycin nucleus of Claim 6 wherein said pseudomycin natural product is selected from the group consisting of pseudomycin A, A', B, B' , C, and C.

8. A process for deacylating an N-acyl side-chain of a syringomycin natural product comprising the step of reacting a syringomycin natural product with a deacylating enzyme selected from the group consisting of ECB deacylase and polymyxin acylase to produce a syringomycin nucleus.

9. The process of Claim 7 wherein said syringomycin nucleus is represented by either structure III or IV

III

IV or a pharmaceutically acceptable salt, hydrate or solvate thereof .

10. A syringomycin nucleus prepared by reacting a syringomycin natural product with a deacylating enzyme selected from the group consisting of ECB deacylase and polymyxin acylase.

11. A compound having the following structure or a pharmaceutically acceptable salt, hydrate or solvate thereof .

12. A compound having the following structure

or a pharmaceutically acceptable salt, hydrate or solvate thereof .